Abstract
Post-traumatic stress disorder (PTSD) is an anxiety disorder that develops after experiencing trauma. Actual therapies do not help majority of patients with PTSD. Moreover, extinguished fear memories usually reappear in the individuals when exposed to trauma cues. New drugs to reduce the impact of conditioned cues in eliciting abnormal fear responses are urgently required. Cotinine, the main metabolite of nicotine, decreased anxiety and depressive-like behavior, and enhanced fear extinction in mouse models of PTSD. Cotinine, considered a positive modulator of the α7 nicotinic acetylcholine receptor (α7nAChR), enhances fear extinction in rodents in a manner dependent on the activity of the αnAChRs. Cotinine stimulates signaling pathways downstream of α7nAChR including the protein kinase B (Akt)/glycogen synthase kinase 3β (GSK3β) pathway and the extracellular signal-regulated kinases (ERKs). The stimulation of these factors promotes synaptic plasticity and the extinction of fear. In this review, we discuss the hypothesis that cotinine relieves PTSD symptoms and facilitates fear memory extinction by promoting brain plasticity through the positive modulation of presynaptic nAChRs and its effectors in the brain.
Keywords: Anxiety, depressive-like behavior, fear extinction, tobacco, trauma.
Current Pharmaceutical Design
Title:Nicotine-Derived Compounds as Therapeutic Tools Against Post-Traumatic Stress Disorder
Volume: 21 Issue: 25
Author(s): George E Barreto, Alexander Yarkov, Marcos Avila-Rodriguez, Gjumrakch Aliev and Valentina Echeverria
Affiliation:
Keywords: Anxiety, depressive-like behavior, fear extinction, tobacco, trauma.
Abstract: Post-traumatic stress disorder (PTSD) is an anxiety disorder that develops after experiencing trauma. Actual therapies do not help majority of patients with PTSD. Moreover, extinguished fear memories usually reappear in the individuals when exposed to trauma cues. New drugs to reduce the impact of conditioned cues in eliciting abnormal fear responses are urgently required. Cotinine, the main metabolite of nicotine, decreased anxiety and depressive-like behavior, and enhanced fear extinction in mouse models of PTSD. Cotinine, considered a positive modulator of the α7 nicotinic acetylcholine receptor (α7nAChR), enhances fear extinction in rodents in a manner dependent on the activity of the αnAChRs. Cotinine stimulates signaling pathways downstream of α7nAChR including the protein kinase B (Akt)/glycogen synthase kinase 3β (GSK3β) pathway and the extracellular signal-regulated kinases (ERKs). The stimulation of these factors promotes synaptic plasticity and the extinction of fear. In this review, we discuss the hypothesis that cotinine relieves PTSD symptoms and facilitates fear memory extinction by promoting brain plasticity through the positive modulation of presynaptic nAChRs and its effectors in the brain.
Export Options
About this article
Cite this article as:
Barreto E George, Yarkov Alexander, Avila-Rodriguez Marcos, Aliev Gjumrakch and Echeverria Valentina, Nicotine-Derived Compounds as Therapeutic Tools Against Post-Traumatic Stress Disorder, Current Pharmaceutical Design 2015; 21 (25) . https://dx.doi.org/10.2174/1381612821666150710145250
DOI https://dx.doi.org/10.2174/1381612821666150710145250 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanisms Involved in BACE Upregulation Associated to Stress
Current Alzheimer Research Cinnamic Acid Derivatives in Tuberculosis, Malaria and Cardiovascular Diseases - A Review
Current Organic Chemistry Identification of New Pancreatic Beta Cell Targets for In Vivo Imaging by a Systems Biology Approach
Current Pharmaceutical Design Circulating Biochemical Markers of Brain Damage in Infants Complicated by Ischemia Reperfusion Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Could Targeting HMGB1 be Useful for the Clinical Management of COVID-19 Infection?
Combinatorial Chemistry & High Throughput Screening How to Manage the Infectious Risk under Anti-TNF in Inflammatory Bowel Disease
Current Drug Targets A Review of the Evidence for a Neuroendocrine Link Between Stress, Depression and Diabetes Mellitus
Current Diabetes Reviews Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD
Current Pharmaceutical Design Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Early Life Vitamin D Status and Lung Development
Current Respiratory Medicine Reviews The Role of Cellular Plasticity in Cancer Development
Current Medicinal Chemistry Recent Patents on Thiazole Derivatives Endowed with Antitumor Activity
Recent Patents on Anti-Cancer Drug Discovery Glioma Stem Cell Maintenance: The Role of the Microenvironment
Current Pharmaceutical Design Tuberculosis, an Old Disease Lacking New Therapeutic Drugs
Current Drug Therapy Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals Genetics and Genomics of Hepatic Acute Phase Reactants: A Mini-Review
Inflammation & Allergy - Drug Targets (Discontinued) Antibodies As Promising Novel Neuroprotective Agents in the Central Nervous System Injuries
Central Nervous System Agents in Medicinal Chemistry Mitochondrial Dysfunction and Its Relationship with mTOR Signaling and Oxidative Damage in Autism Spectrum Disorders
Mini-Reviews in Medicinal Chemistry Plant Secondary Metabolites in Cancer Chemotherapy: Where are We?
Current Pharmaceutical Biotechnology